This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Mortality with Paclitaxel-Coated Devices in Peripheral Artery Disease

Thursday, December 10, 2020

Submitted by


Source Name: The New England Journal of Medicine


Joakim Nordanstig, M.D., Ph.D., Stefan James, M.D., Ph.D., Manne Andersson, M.D., Ph.D., Mattias Andersson, M.D., Peter Danielsson, M.D., Ph.D., Peter Gillgren, M.D., Ph.D., Martin Delle, M.D., Ph.D., Jan Engström, M.D., Torbjörn Fransson, M.D., Maher Hamoud, M.D., Ph.D., Anna Hilbertson, M.D., Patrik Johansson, M.D., Lars Karlsson, M.D., Ph.D., Björn Kragsterman, M.D., Ph.D., Hans Lindgren, M.D., Ph.D., Karin Ludwigs, M.D., Stefan Mellander, M.D., Ph.D., Niklas Nyman, M.D., Henrik Renlund, Ph.D., Birgitta Sigvant, M.D., Ph.D., Per Skoog, M.D., Ph.D., Joachim Starck, M.D., Gustaf Tegler, M.D., Ph.D., Asko Toivola, M.D., Maria Truedson, M.D., Carl-Magnus Wahlgren, M.D., Ph.D., Jonas Wallinder, M.D., Andreas Öjersjö, M.D., and Mårten Falkenberg, M.D., Ph.D.

An ad hoc interim analysis pursuant to previous publications raising concerns on Paclitaxel DCS in chronic critical and not-critical lower limb ischaemia. The short manuscript requires careful reading to form an individual opinion beyond the relatively simple arithmetics: slightly more deaths in the intervention group. The vasculopathic cohort had a 75% crude overall survival after only 2.5 years.

Add comment

Log in or register to post comments